Almirall launches Spain Solaraze r for the treatment of Actinic Keratosis.

-Solaraze ® is emerging as a line of treatment for its proven efficacy and good tolerability profile and is preceded by its success in Germany and United Kingdom, among other countries

Barcelona, 2011-December Almirall launches Spain Solaraze ® for the treatment of Actinic Keratosis, an injury that may be the first stage in the development of skin cancer. It is estimated that one in six people will develop an Actinic Keratosis throughout his life. The elderly are more likely than young people to develop Actinic Keratosis, because cumulative sun exposure increases with age (1).

Solaraze ® is shaping up as a line of treatment of multiple injuries and field of cancerización of Actinic Keratosis, for its demonstrated efficacy and good tolerability profile.

Solaraze ® consolidates the business strategy of Almirall within the dermatology area, where the company is the first pharmaceutical’s prescription in Germany and the eighth in Europe. In fact, Solaraze ® is already available to doctors and patients in countries such as Germany and United Kingdom, where getting an excellent acceptance of the hand of Almirall.

Dermatology and respiratory, two of the key areas of r & d of Almirall along with gastrointestinal presented synergies by autoimmune origin and exemplify the commitment of the company with the innovation

Solaraze ®

Solaraze ® (diclofenac sodium combined with hyaluronic acid), is a specific formulation in the form of gel containing diclofenac sodium 3% with hyaluronic acid as vehiculizante, with a mechanism for multiple action that helps the skin defense system to destroy damaged cellsthus contributing to the healthy cells to replace them.

By its clinical efficacy demonstrated his good profile of safety and tolerability as well as easy as applicable (directly on the skin twice a day for 90 days), Solaraze ® facilitates compliance with the treatment by the patient.

Actinic Keratosis

Actinic Keratosis can be the first stage in the development of skin cancer and, therefore, it is considered a precancerous condition.

Known as solar Keratosis, it manifests as a small bundle with scales or crust on the surface of the skin. The base can be clear or dark, Brown, pink or red, or a combination of them, or the same color as the skin. The scale or crust is hard, dry and rough and detected more easily touch that in view, by feeling a rough surface. Occasionally, it produces a feeling pangs or increased sensitivity.

Actinic Keratosis evolves slowly, for years, and usually appears on the face, ears, scalp, neck, back of the hands and forearms, and on the lips. Its appearance is flat on the skin of the head and neck, and a little bulky at the arms and hands. Often, you have more than one lesion of Actinic Keratosis. The lesions tend not to risk life if it detects and treats in the early stages.

Exposure to the Sun is one of the main causes of actínicas Keratosis. The damage caused by the Sun on the skin is cumulative, which means shorter exposure joins all that experience in life since childhood.

Almirall

Almirall is an international pharmaceutical company based on innovation and committed to health. With headquarters in Barcelona (Spain), Almirall researches, develops, produces and sells drugs own r & d and licensing with the aim of improving the health and well-being of people.

The therapeutic areas in which concentrates its resources in research are related to the treatment of asthma, COPD (chronic obstructive pulmonary disease), gastrointestinal disorders, psoriasis and other skin complaints forms.

Almirall drugs are currently present in over 70 countries. It has direct presence in Europe and Latin America through 12 subsidiaries.